Video
Dr. William Huang on UGN-102 in non–muscle-invasive bladder cancer
Author(s):
“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.
Video Player is loading.
In this interview, recorded at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana, William C. Huang, MD, discusses the OPTIMA II and ENIVISION trials evaluating UGN-102 in non–muscle-invasive bladder cancer. Huang is professor and vice chair for clinical affairs in the Department of Urology at NYU Grossman School of Medicine in New York, New York.
Related Videos
5 key trial insights from AUA 2025
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
